The Danilov lab focuses on early drug development in lymphoid malignancies, with a goal of ushering novel therapeutic approaches into clinic. The team follows the "bench to bedside" paradigm, where pre-clinical findings in the laboratory lead to initiation of early phase clinical trials in lymphoma. Subsequently, correlative studies advance understanding of cancer biology and drug pharmacodynamics, spurring progress in the field of molecular therapeutics. The lab investigates mechanistic aspects of targeted therapies and their immunomodulatory effects.
A Phase Ib/II study of Syk inhibitor entospletinib (GS-9973) in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell malignancies
A Phase I Study of pevonedistat (MLN4924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
A Phase II study of BTK inhibitor acalabrutinib in CLL and autoimmune hemolytic anemia
A Phase II study of PI3K inhibitor duvelisib in CLL
Effect of comorbidities on treatment outcomes in chronic lymphocytic leukemia